PharmCAT.NET

Biostatistics, pharmacokinetics and clinical trials.

  • Home page
  • Blog
  • Contacts
  • Agreement & Confidentiality

IBM SPSS Extension: R Project PowerTOST library

Posted on December 31, 2018December 31, 2018 by frozencat

IBM SPSS Extension PowerTOST R Project library. Syntax command: POWERTOST.

Version: 1.0.0

Functions:

  • power.TOST
  • sampleN.TOST
  • CVfromCI

Дизайны:

  • parallel
  • 2×2
  • 2x2x4

Скачать/Download

GitHUB: https://github.com/PharmCat/SPSSPowerTOST

Categories: Blog, SPSS

Post navigation

Next Post:

Recent Posts

  • IBM SPSS + R Project: Confidence intervals for proportions, independent groups
  • IBM SPSS Extension: R Project PowerTOST library

Галерея

IMG-20170730-WA0010
20180815 150824
20170802 000553
IMG-20170806-WA0003
IMG-20170807-WA0038
20180814 182629
  • Drug Shortages
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-24 By FDA
  • Supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Submissions During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (Revised)
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-03-24 By FDA
  • FDA approves first treatment for activated phosphoinositide 3-kinase delta syndrome
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-24 By FDA
  • Drug Safety and Risk Management Advisory Committee Roster
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-24 By FDA
  • Blood Products Advisory Committee April 26, 2023 Meeting Announcement - 04/26/2023
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-03-24 By FDA
  • GDUFA Implementation Quarterly Meetings between FDA and Industry
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-24 By FDA
  • Over-the-Counter (OTC) Drug Review | OTC Monograph Reform in the CARES Act
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-24 By FDA
  • Human medicines European public assessment report (EPAR): Imraldi, adalimumab, Spondylitis, Ankylosing;Arthritis, Rheumatoid;Uveitis;Colitis, Ulcerative;Psoriasis;Arthritis, Psoriatic;Crohn Disease;Hidradenitis Suppurativa;Arthritis, Date of authorisation: 24/08/2017, Revision: 20, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-24
  • Drug Compounding and Drug Shortages
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-24 By FDA
  • Over-The-Counter Monograph Drug User Fee Program (OMUFA)
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-24 By FDA
  • FDA Updates and Press Announcements on NDMA in Zantac (ranitidine)
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-24 By FDA
  • Dermatologic and Ophthalmic Drugs Advisory Committee Roster
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-24 By FDA
  • Methods and Approaches for Capturing Post-Approval Safety and Efficacy Data on Cell and Gene Therapy Products - 04/27/2023
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-03-23 By FDA
  • FDA CDER & JHU CERSI Workshop | Addressing Challenges in the Design and Analysis of Rare Disease Clinical Trials: Considerations and Tools - 05/02/2023
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-23 By FDA
  • Immune Globulin Hypersensitivity Reactions: Root Causes and Mitigation; Public Workshop - 03/30/2023
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-03-23 By FDA
Older posts
Theme: Scaffold by Danny Cooper.